The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBPET.L Regulatory News (BPET)

  • There is currently no data for BPET

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Conversion of Securities

2 Jun 2006 12:08

F&C Private Equity Trust PLC02 June 2006 To: RNSDate: 2 June 2006 F&C Private Equity Trust plcThird Conversion of C Shares The third conversion of 'C' shares into 'B' shares is by reference to 30 April2006. The NAVs per 'B' share and per 'C' share as at that date, calculated forthe purpose of conversion in accordance with the articles of association*, were110.42p and 159.80p respectively. As at 30 April 2006, the net assets of the'C' pool, valued for the purpose of conversion, were £23.2 million, of which59.8% was represented by cash assets. Consequently 12.6 million 'C' shares willconvert to 8.7 million 'B' shares at the third conversion date. The conversionratio (being the number of 'B' shares resulting from the 'C' shares to beconverted) is 0.69098890. The number of 'C' shares to be converted into 'B' shares in each holding of 'C'shares as at 8 June 2006 (the record date for the third conversion) will berounded down to the nearest whole 'C' share. Fractional entitlements to 'B'shares arising on conversion will not be allocated, and will be aggregated andsold in the market for the benefit of the 'B' pool. For illustrative purposesonly, a holder of 1,000 'C' shares as at 8 June 2006 will, immediately followingthe third conversion, hold 413 'B' shares and 402 'C' shares. The third conversion will occur with effect from 9 June 2006. Applications have been made to the Financial Services Authority and to LondonStock Exchange plc for the 'B' shares arising on the second conversion to beadmitted to the Official List and to trading on the main market of London StockExchange plc respectively. It is expected that such admissions will becomeeffective on 9 June 2006. In order to facilitate the conversion, the balance of 'C' shares remainingunconverted will transfer to ISIN GB00B15C4726 and SEDOL B15C472 upon admissionof the new 'B' shares on 9 June 2006. * The quarterly NAVs value listed investments at their bid prices. The dailyNAV per 'C' share and the NAVs per 'B' share and per 'C' share for the purposeof conversion value listed investments at their mid-market prices. For further information, please contact: Hamish Mair 0131 465 1184hamish.mair@fandc.com Martin Cassels 0131 465 1095martin.cassels@fandc.com Alistair Moreton, Arbuthnot Securities Ltd 0207 012 2000 Sue Inglis, Intelli Corporate Finance 0207 653 6300 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Jun 20223:22 pmRNSChange of Name
17th Jun 20224:07 pmRNSTransaction in Own Shares
15th Jun 20225:01 pmRNSTransaction in Own Shares
27th May 20229:08 amRNSResult of Annual Gen Meeting & Directorate Change
26th May 202212:02 pmRNS1st Quarter Results
27th Apr 202210:07 amRNSDirector/PDMR Shareholding
27th Apr 202210:06 amRNSDirector/PDMR Shareholding
27th Apr 202210:04 amRNSDirector/PDMR Shareholding
26th Apr 20223:24 pmRNSDirector/PDMR Shareholding
26th Apr 20223:23 pmRNSDirector/PDMR Shareholding
25th Apr 20229:24 amRNSDirector/PDMR Shareholding
8th Apr 20227:00 amRNSAnnual Financial Report
1st Apr 202210:17 amRNSHolding(s) in Company
1st Apr 202210:09 amRNSHolding(s) in Company
30th Mar 20222:56 pmRNSDirector/PDMR Shareholding
30th Mar 20222:54 pmRNSDirector/PDMR Shareholding
25th Mar 20227:00 amRNSAnnual Financial Report
17th Feb 20227:00 amRNSDirectorate Change
14th Jan 20227:00 amRNSUpdate on Secondary Placing
13th Jan 20227:00 amRNSProposed Secondary Placing
4th Jan 20227:00 amRNSInvestor Presentation
26th Nov 20217:00 amRNS3rd Quarter Results
22nd Nov 202110:47 amRNSHolding(s) in Company
15th Oct 20219:55 amRNSHolding(s) in Company
15th Oct 20217:00 amRNSKepler Trust Intelligence: New Research
27th Aug 20217:00 amRNSInterim results and Quarterly Dividend
25th Jun 20213:14 pmRNSHolding(s) in Company
27th May 20212:15 pmRNSAGM Statement
27th May 202111:51 amRNSQuarterly NAV and Dividend Announcement
29th Apr 20211:01 pmRNSHolding(s) in Company
19th Apr 20217:00 amRNSAnnual Financial Report
26th Mar 20217:00 amRNSFinal Results
24th Mar 20217:00 amRNSInvestment Update
8th Feb 20213:00 pmRNSHolding(s) in Company
9th Dec 20209:22 amRNSHolding(s) in Company
27th Nov 202010:52 amRNSHolding(s) in Company
25th Nov 20209:18 amRNSKepler Trust Intelligence: New Research
20th Nov 20207:00 amRNSQuarterly results and dividend announcement
15th Oct 20204:09 pmRNSNon-Executive Director Declaration
18th Sep 20202:09 pmRNSDirector/PDMR Shareholding
16th Sep 20202:24 pmRNSDirector/PDMR Shareholding
15th Sep 20203:42 pmRNSHolding(s) in Company
1st Sep 202012:24 pmRNSDirector/PDMR Shareholding
21st Aug 20207:00 amRNSInterim Results
20th Jul 20207:00 amRNSNon-Executive Director Declaration
17th Jul 20207:00 amRNSAppointment of Corporate Broker
9th Jun 20209:57 amRNSHolding(s) in Company
4th Jun 20207:00 amRNSDirectorate Change
22nd May 20204:11 pmRNSHolding(s) in Company
21st May 20207:00 amRNSFirst Quarter Results and Dividend Announcement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.